MX2022000603A - Anticuerpo anti-tau y uso del mismo. - Google Patents

Anticuerpo anti-tau y uso del mismo.

Info

Publication number
MX2022000603A
MX2022000603A MX2022000603A MX2022000603A MX2022000603A MX 2022000603 A MX2022000603 A MX 2022000603A MX 2022000603 A MX2022000603 A MX 2022000603A MX 2022000603 A MX2022000603 A MX 2022000603A MX 2022000603 A MX2022000603 A MX 2022000603A
Authority
MX
Mexico
Prior art keywords
tau
tau antibody
present
antibody according
same
Prior art date
Application number
MX2022000603A
Other languages
English (en)
Inventor
Seung-Yong Yoon
Original Assignee
Adel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adel Inc filed Critical Adel Inc
Publication of MX2022000603A publication Critical patent/MX2022000603A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)

Abstract

La presente invención se refiere a un anticuerpo anti-tau que se une específicamente a una proteína tau y sus usos. El anticuerpo anti-tau de acuerdo con la presente invención puede unirse específicamente a una proteína tau en la que la lisina 280 está acetilada, y puede suprimir la agregación anormal de proteínas tau. Además, el anticuerpo anti-tau de acuerdo con la presente invención, cuando se administra a un modelo animal de demencia inducido, puede mejorar la función locomotriz y capacidad cognitiva en el modelo animal. Por lo tanto, el anticuerpo anti-tau de acuerdo con la presente invención se puede usar en la prevención o tratamiento de enfermedades neurodegenerativas.
MX2022000603A 2019-07-15 2020-07-13 Anticuerpo anti-tau y uso del mismo. MX2022000603A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190085233 2019-07-15
PCT/KR2020/009207 WO2021010712A1 (ko) 2019-07-15 2020-07-13 항-타우 항체 및 이의 용도

Publications (1)

Publication Number Publication Date
MX2022000603A true MX2022000603A (es) 2022-05-20

Family

ID=74088428

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000603A MX2022000603A (es) 2019-07-15 2020-07-13 Anticuerpo anti-tau y uso del mismo.

Country Status (14)

Country Link
US (1) US20220204601A1 (es)
EP (1) EP4001305A4 (es)
JP (1) JP2022541539A (es)
KR (1) KR102196840B1 (es)
CN (1) CN114430744B (es)
AU (1) AU2020313751A1 (es)
BR (1) BR112022000719A2 (es)
CA (1) CA3143811A1 (es)
CL (1) CL2022000087A1 (es)
GB (1) GB2600599A (es)
IL (1) IL289813A (es)
MX (1) MX2022000603A (es)
TW (1) TW202116801A (es)
WO (1) WO2021010712A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6674888B2 (ja) 2013-03-13 2020-04-01 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
EA201892417A1 (ru) 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
FI3452507T3 (fi) 2016-05-02 2022-12-15 Tau-immuunihoito
CN110881274A (zh) 2017-05-02 2020-03-13 普罗塞纳生物科学有限公司 识别tau的抗体
BR112021016947A2 (pt) 2019-03-03 2021-11-03 Prothena Biosciences Ltd Anticorpos que reconhecem tau
WO2023039456A1 (en) * 2021-09-09 2023-03-16 The University Of North Carolina At Chapel Hill Monoclonal antibodies targeting acetylated tau and methods of use thereof
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023229445A1 (ko) * 2022-05-27 2023-11-30 주식회사 진큐어 신규 펩타이드 및 그의 용도
WO2024123052A1 (ko) * 2022-12-08 2024-06-13 주식회사 아델 항-타우 항체 및 펩티드를 포함하는 융합체와 그의 용도
CN116716352A (zh) * 2023-05-16 2023-09-08 深圳湾实验室 Tau蛋白聚集的细胞模型、其构建方法及应用
CN116693682B (zh) * 2023-06-02 2024-04-19 涌源合生科技(深圳)有限公司 抗Tau蛋白抗体及其制备方法和用途
CN116948025B (zh) * 2023-09-14 2024-04-02 北京凯祥弘康生物科技有限公司 一种抗Tau蛋白的抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130251731A1 (en) * 2012-03-22 2013-09-26 The Trustees Of The University Of Pennsylvania Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies
CA2869438C (en) * 2012-04-05 2021-08-17 Ac Immune S.A. Humanized tau antibody
RU2668159C2 (ru) * 2012-07-03 2018-09-26 Вашингтон Юниверсити Антитела против тау
TWI664190B (zh) * 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
JO3576B1 (ar) * 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
WO2018106889A1 (en) * 2016-12-09 2018-06-14 Cogwellin L.L.C. Diagnosis of alzheimer's disease
KR102032314B1 (ko) * 2016-12-21 2019-10-16 주식회사 아델 변이된 타우 단백질 단편 및 이의 용도

Also Published As

Publication number Publication date
JP2022541539A (ja) 2022-09-26
EP4001305A1 (en) 2022-05-25
GB202201160D0 (en) 2022-03-16
CA3143811A1 (en) 2021-01-21
GB2600599A (en) 2022-05-04
IL289813A (en) 2022-03-01
CL2022000087A1 (es) 2023-03-10
EP4001305A9 (en) 2023-05-24
TW202116801A (zh) 2021-05-01
US20220204601A1 (en) 2022-06-30
BR112022000719A2 (pt) 2022-03-29
CN114430744B (zh) 2024-06-21
AU2020313751A1 (en) 2022-02-10
CN114430744A (zh) 2022-05-03
WO2021010712A1 (ko) 2021-01-21
EP4001305A4 (en) 2022-10-12
KR102196840B1 (ko) 2020-12-30

Similar Documents

Publication Publication Date Title
MX2022000603A (es) Anticuerpo anti-tau y uso del mismo.
MX2019007480A (es) Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau.
WO2016079597A8 (en) Humanized tau antibodies in alzheimer's disease
MX2019013537A (es) Compuestos para la prevencion y el tratamiento de enfermedades y el uso de los mismos.
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
MA45543B1 (fr) Anticorps anti-peptide bêta-amyloïde n3pglu et leurs utilisations
BR112022009317A2 (pt) Anticorpos de cd73 biparatópicos
MX2020007527A (es) Tratamiento de enfermedades oftalmologicas.
WO2018208011A3 (ko) β-아밀로이드 단백질의 응집을 억제하는 생체친화적 펩타이드
BR112016017344A2 (pt) Amidas de heteroaril como inibidores de agregação de proteínas
WO2019045248A3 (ko) 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
MA45172B1 (fr) Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
MX2021008207A (es) Proteínas de fusión multifuncionales y usos de las mismas.
EA202092557A1 (ru) СОЕДИНЕНИЯ ТЕТРАГИДРОБЕНЗОФУРО[2,3-c]ПИРИДИНА И БЕТА-КАРБОЛИНА ДЛЯ ЛЕЧЕНИЯ, ОБЛЕГЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАССТРОЙСТВ, СВЯЗАННЫХ С АГРЕГАТАМИ ТАУ-БЕЛКА
EA201992688A1 (ru) Средства, пути применения и способы лечения
AU2016210835A8 (en) Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
EP3773547A4 (en) IDENTIFICATION OF GRANINES AS A PATHOGENIC FACTOR OF ALZHEIMER'S MORBUS AND COMPOSITIONS AND METHODS FOR INHIBITING GRANINE AGGREGATION AND TREATMENT OF ALZHEIMER'S MORBUS
WO2017197253A3 (en) Peptides and methods for treating neurodegenerative disorders
MX2022004143A (es) Compuesto que tiene actividad inhibidora de brd4, su método de preparación y su uso.
IL290074A (en) Peptides for use in the treatment of macular degeneration and other ocular disorders
WO2020186155A3 (en) Synthetic neuromodulatory peptides
MX2021011596A (es) Compuestos y composiciones como moduladores de se?alizacion tlr.
EP4061403A4 (en) SECRETABLE PROTEIN-INDUCED IMMUNE TOLERANCE AND TREATMENT OF AUTOIMMUNE, ALLERGIC AND OTHER DISEASES AND DISORDERS
JP2016539911A5 (es)
EP3802568A4 (en) PEPTIDE THERAPEUTIC AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED CONDITIONS